CL2020000860A1 - Compuestos monobactámicos cromanos para el tratamiento de infecciones bacterianas. - Google Patents
Compuestos monobactámicos cromanos para el tratamiento de infecciones bacterianas.Info
- Publication number
- CL2020000860A1 CL2020000860A1 CL2020000860A CL2020000860A CL2020000860A1 CL 2020000860 A1 CL2020000860 A1 CL 2020000860A1 CL 2020000860 A CL2020000860 A CL 2020000860A CL 2020000860 A CL2020000860 A CL 2020000860A CL 2020000860 A1 CL2020000860 A1 CL 2020000860A1
- Authority
- CL
- Chile
- Prior art keywords
- chroman
- treatment
- bacterial infections
- pharmaceutically acceptable
- refers
- Prior art date
Links
- 208000035143 Bacterial infection Diseases 0.000 title abstract 2
- 208000022362 bacterial infectious disease Diseases 0.000 title abstract 2
- -1 Chroman monobactam compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762566779P | 2017-10-02 | 2017-10-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020000860A1 true CL2020000860A1 (es) | 2020-08-14 |
Family
ID=65994576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020000860A CL2020000860A1 (es) | 2017-10-02 | 2020-03-31 | Compuestos monobactámicos cromanos para el tratamiento de infecciones bacterianas. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US11433055B2 (enExample) |
| EP (1) | EP3691639B1 (enExample) |
| JP (1) | JP7252948B2 (enExample) |
| KR (1) | KR102425959B1 (enExample) |
| CN (2) | CN118496221A (enExample) |
| AU (1) | AU2018345523B2 (enExample) |
| CA (1) | CA3076022C (enExample) |
| CL (1) | CL2020000860A1 (enExample) |
| CO (1) | CO2020004087A2 (enExample) |
| CR (1) | CR20200148A (enExample) |
| DO (1) | DOP2020000058A (enExample) |
| EA (1) | EA202090604A1 (enExample) |
| ES (1) | ES2968467T3 (enExample) |
| GE (1) | GEP20227406B (enExample) |
| IL (1) | IL273306B (enExample) |
| JO (1) | JOP20200130A1 (enExample) |
| MA (1) | MA50629A (enExample) |
| MX (1) | MX2020003581A (enExample) |
| NI (1) | NI202000023A (enExample) |
| PE (1) | PE20201256A1 (enExample) |
| PH (1) | PH12020550107A1 (enExample) |
| SA (1) | SA520411571B1 (enExample) |
| SG (1) | SG11202002575UA (enExample) |
| UA (1) | UA126000C2 (enExample) |
| WO (1) | WO2019070492A1 (enExample) |
| ZA (1) | ZA202001721B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110156697B (zh) * | 2019-05-30 | 2022-05-06 | 常州沃腾化工科技有限公司 | 一种1,2-二甲基-1,4,5,6-四氢嘧啶的合成方法 |
| US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
| WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| HRP20250814T1 (hr) | 2020-07-02 | 2025-09-12 | Incyte Corporation | Spojevi tricikličke uree kao jak2 v617f inhibitori |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| US20240051931A1 (en) * | 2020-12-03 | 2024-02-15 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Hdac inhibitors |
| WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
| CA3211748A1 (en) | 2021-02-25 | 2022-09-01 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
| EP4431113A4 (en) * | 2021-11-09 | 2025-10-22 | Inst Med Biotechnology Cams | PHARMACEUTICAL COMPOSITION CONTAINING A ß-LACTAM COMPOUND AND USE THEREOF |
| CR20240212A (es) | 2021-11-18 | 2024-07-01 | Merck Sharp & Dohme Llc | Compuestos monobactámicos de cromano amidina para tratar las infecciones bacterianas |
| JP7671398B2 (ja) * | 2021-11-18 | 2025-05-01 | メルク・シャープ・アンド・ドーム・エルエルシー | クロマンアミジンモノバクタム抗生物質 |
| IL315647A (en) | 2022-03-17 | 2024-11-01 | Incyte Corp | Tricyclic urea compounds as Jak2 and 617f inhibitors |
| EP4558137A2 (en) * | 2022-07-18 | 2025-05-28 | Merck Sharp & Dohme LLC | Chromane amidine monobactam compounds for the treatment of bacterial infections |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4684722A (en) | 1986-01-06 | 1987-08-04 | E. R. Squibb & Sons, Inc. | Monosulfactams |
| US5250691A (en) | 1991-09-09 | 1993-10-05 | E. R. Squibb & Sons, Inc. | Heteroaryl derivatives of monocyclic beta-lactam antibiotics |
| SI1965798T1 (sl) | 2005-12-07 | 2012-01-31 | Basilea Pharmaceutica Ag | Uporabni monobaktamski antibiotiki |
| EP1938822A1 (en) * | 2006-12-21 | 2008-07-02 | Novartis AG | Combination therapy for the treatment of airways disease |
| TR201812636T4 (tr) | 2010-10-11 | 2018-09-21 | Biogen Int Neuroscience Gmbh | İnsan anti-tau antikorları. |
| DK2646436T3 (en) | 2010-11-29 | 2015-06-29 | Pfizer | monobactams |
| UY34585A (es) * | 2012-01-24 | 2013-09-02 | Aicuris Gmbh & Co Kg | Compuestos b-lactámicos sustituidos con amidina, su preparación y uso |
| WO2013180238A1 (ja) | 2012-05-31 | 2013-12-05 | 公立大学法人大阪市立大学 | 認知症治療剤又は予防剤 |
| US20140275007A1 (en) | 2013-03-14 | 2014-09-18 | Rempex Pharmaceuticals, Inc. | Oxamazin antibiotics |
| US20160326157A1 (en) | 2014-01-06 | 2016-11-10 | President And Fellows Of Harvard College | Monobactams and methods of their synthesis and use |
| ES2719136T3 (es) | 2014-03-24 | 2019-07-08 | Novartis Ag | Compuestos orgánicos de monobactam para el tratamiento de infecciones bacterianas |
| TWI734975B (zh) | 2014-06-27 | 2021-08-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗-tau抗體 |
| MY194313A (en) * | 2014-10-31 | 2022-11-27 | Galapagos Nv | Substituted chromanes and method of use |
| FR3031423B1 (fr) * | 2015-01-06 | 2018-11-30 | Centre National De La Recherche Scientifique | Procede et dispositif de conversion de courant et vehicule comportant un tel dispositif |
| KR20180093925A (ko) | 2015-12-15 | 2018-08-22 | 머크 샤프 앤드 돔 코포레이션 | 박테리아 감염을 치료하기 위한 비아릴 모노박탐 화합물 및 그의 사용 방법 |
| MX2018010878A (es) * | 2016-03-07 | 2018-11-09 | Merck Sharp & Dohme | Compuestos de aril-monobactam biciclicos y metodos de uso de los mismos para el tratamiento de infecciones bacterianas. |
-
2018
- 2018-09-27 MA MA050629A patent/MA50629A/fr unknown
- 2018-09-27 ES ES18864229T patent/ES2968467T3/es active Active
- 2018-09-27 MX MX2020003581A patent/MX2020003581A/es unknown
- 2018-09-27 SG SG11202002575UA patent/SG11202002575UA/en unknown
- 2018-09-27 EP EP18864229.2A patent/EP3691639B1/en active Active
- 2018-09-27 AU AU2018345523A patent/AU2018345523B2/en active Active
- 2018-09-27 CN CN202410563311.2A patent/CN118496221A/zh active Pending
- 2018-09-27 EA EA202090604A patent/EA202090604A1/ru unknown
- 2018-09-27 WO PCT/US2018/053039 patent/WO2019070492A1/en not_active Ceased
- 2018-09-27 CN CN201880064269.2A patent/CN111201021B/zh active Active
- 2018-09-27 US US16/651,456 patent/US11433055B2/en active Active
- 2018-09-27 GE GEAP201815303A patent/GEP20227406B/en unknown
- 2018-09-27 PE PE2020000692A patent/PE20201256A1/es unknown
- 2018-09-27 CA CA3076022A patent/CA3076022C/en active Active
- 2018-09-27 JP JP2020518661A patent/JP7252948B2/ja active Active
- 2018-09-27 JO JOP/2020/0130A patent/JOP20200130A1/ar unknown
- 2018-09-27 UA UAA202002037A patent/UA126000C2/uk unknown
- 2018-09-27 CR CR20200148A patent/CR20200148A/es unknown
- 2018-09-27 KR KR1020207012234A patent/KR102425959B1/ko active Active
-
2020
- 2020-03-15 IL IL273306A patent/IL273306B/en unknown
- 2020-03-16 DO DO2020000058A patent/DOP2020000058A/es unknown
- 2020-03-18 ZA ZA2020/01721A patent/ZA202001721B/en unknown
- 2020-03-19 SA SA520411571A patent/SA520411571B1/ar unknown
- 2020-03-20 PH PH12020550107A patent/PH12020550107A1/en unknown
- 2020-03-24 NI NI202000023A patent/NI202000023A/es unknown
- 2020-03-31 CO CONC2020/0004087A patent/CO2020004087A2/es unknown
- 2020-03-31 CL CL2020000860A patent/CL2020000860A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020000860A1 (es) | Compuestos monobactámicos cromanos para el tratamiento de infecciones bacterianas. | |
| MX2018005382A (es) | Compuestos de biaril-monobactam y metodos de uso de los mismos para el tratamiento de infecciones bacterianas. | |
| MX2018010878A (es) | Compuestos de aril-monobactam biciclicos y metodos de uso de los mismos para el tratamiento de infecciones bacterianas. | |
| DOP2019000201A (es) | Compuestos inhibidores del vih | |
| CR11510A (es) | Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| EA201692506A3 (ru) | Ингибиторы репликации вирусов гриппа | |
| CL2011000504A1 (es) | Compuestos derivados de piridin-4-il-tiazol-2il-amida 2-amida-pirrolidin-1,2-dicarboxilico, inhibidores de quinasa de fosfatidil-inositol-3; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de un medicamento para el tratamiento del cancer. | |
| CL2017003325A1 (es) | Derivados de 3-tetrazolilo-benceno-1,2-disulfonamida como inhibidores de metalo-beta-lactamasa | |
| BR112012009215A2 (pt) | "terapia combinada contra o cancer com compostos inibidores de hsp90" | |
| AR099632A1 (es) | Tratamiento de una infección viral de hepatitis c, que usa una combinación de compuestos | |
| NI200900184A (es) | Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer. | |
| BR112013032711A2 (pt) | composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase | |
| AR101740A1 (es) | Terapia de combinación y composiciones | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| BR112017005242A2 (pt) | composto, composição farmacêutica, e, composto para uso. | |
| MY202884A (en) | Compounds useful in hiv therapy | |
| MX2015012472A (es) | Derivados de manosa para el tratamiento de infecciones bacterianas. | |
| BR112018070536A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição | |
| MX2020004930A (es) | Compuestos de biarilo sustituido novedosos como inhibidores de indolamina 2,3-dioxigenasa (ido). | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| MX2018014080A (es) | Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia. | |
| BR112019024549A2 (pt) | compostos derivados de glicopeptídeo e usos dos mesmos | |
| BR112019004236A2 (pt) | compostos para tratar doenças associadas a uma disfunção mitocondrial |